COMP <GO>
LGND vs ABBV // ENTERPRISE SCALE & MARKET CAP
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LGND 6
— ABBV 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $322.75 (+1.71%) • MKT CAP: $6.33B
market-cap
$6.33B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | 29.00% | -26.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 0.77% | 3.47% | -2.70 | ABBV | /fcf-yield <GO> |
| Operating Margin | 15.30% | 24.60% | -9.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 46.40% | 6.90% | +39.50 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 60.40% | 8.60% | +51.80 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 5.33 | +3.07 | LGND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | LGND | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.4 | 72.8 | -9.39 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 113.1x | -70.40 | LGND | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $6.33B | $513.86B | -$507.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | ABBV REV | LGND GROSS % | ABBV GROSS % | LGND FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $61.16B | 44.0% | 70.2% | $48.9M | $17.82B |
| FY 2024 | $167.1M | $56.33B | 44.0% | 70.0% | $95.2M | $17.83B |
| FY 2023 | $131.3M | $54.32B | 44.0% | 44.0% | $43.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
ABBV // BETA 1.15